Total
0
Shares
Image Sourced PainChek Limited
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PainChek has secured a distribution agreement with Person Centred Software to release its facial recognition tool in the United Kingdom
  • This newe product will help more than 850,000 dementia suffers in the UK
  • Data analytics are used to determine the source and severity of pain by analysing the patients face

PainChek Limited has secured a binding distribution agreement with Person Centred Software to expand its PainChek tool to the UK market.

This agreement will allow PainChek’s tool to be distributed to Person’s strong customer base of more than 1,200 aged care providers and 40,000 residents.

It will be distributed through its sale, marketing and service capabilities, in the hopes to provide carers with a quick and easy transition into pain assessment.

Person Centred Software is designed to give carers more time to spend with their clients. Everything is recorded electronically with a few taps on a device so less paperwork needs to be completed and less time is spent away from the patients.

“We are delighted to be working with Person Centred Software. Their team and product offering is highly complimentary to PainChek and together we can leverage the positive learnings and market acceptance from Australia into an even larger market. The agreement will provide us with rapid access to their large UK client base,” CEO, PainChek, Phillip Daffas said.

The application uses the smartphone camera to record a short video of the patients face and then analyses the images using facial recognition. The facial muscle movements that indicate pain are automatically recognised and taken note of.

Carers then record their observations of the pain related to past behaviours such as how the person is moving and vocalising pain. PainChek will then calculate an overall pain score and stores the result allowing the carer to monitor the medication and treatments over time.

While for now it is primarily used for dementia sufferers who can’t speak it is believed PainChek is looking for ways to adapt it to children who have not yet learned how to speak.

PainChek has been granted clearance for the European Union where there is an estimated 7.5 million people living with dementia, 850,000 in the UK, and more than 20 million carers.

The board of PainChek has discussed to setting up operations in the UK in the near future, believing it to be an extremely beneficial opportunity.

“We are establishing a core PainChek UK team who can take advantage of the large European market opportunity and work with strategic partners, like Person Centred Software, on a country by country basis,” Phillip said.

This announcement sent PainChek’s shares rise 32.9 percent to currently sit at 12 cents per share.

PCK by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Nuix (NXL) - Outgoing Group CEO Rod Vawdrey

" Nuix (ASX:NXL) appoints new members to its board

Nuix (NXL) has seen a company reshuffle, appointing new members to its board.

" AL3D (ASX:AL3) sells Arcemy 3D printer to University of Queensland

AL3D Limited (AL3) has sold one of its Arcemy WAM printing units to the University of Queensland (UQ) for around $400,000.

" EP&T Global (ASX:EPX) forecasts 85pc ARR growth for FY22

EP&T Global (EPX) expects the company’s annualised recurring revenue (ARR) to grow by 85 per cent in the 2022 financial year.